A phase II study was undertaken to evaluate the effectiveness of idelalisb plus rituximab in older patients with chronic lymphocytic leukaemia or small lymphocytic leukaemia who were treatment naïve was undertaken. Patients (n = 64) were enrolled in the study. The median age of patients was 71 years. The overall response rate (ORR) was 97% of which 19% were complete responses. In patients with del(17p)/TP53 mutations, the ORR was 100%; it was 97% in those with unmutated IGHV. At 36 months, progression-free survival was 97%.
Read more here.